Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)    
Revenues, net $ 214,539 $ 134,899
Operating expenses:    
Cost of goods sold 25,184 0
Research and development 352,333 161,919
Selling, general and administrative 775,453 886,083
Impairment of intellectual property 6,374 0
Depreciation and amortization 11,195 24,843
Total operating expenses 1,170,539 1,072,845
Loss from operations (956,000) (937,946)
Other income (expenses):    
Interest expense - related parties (135,448) (160,128)
Interest expense, net (31,041) (87,483)
Loss on settlement of debt (100,000) (132,514)
Grant income 362,597 413,979
Change in fair value of upfront purchase price liability 0 (4,500)
Change in fair value of royalty liability 0 (2,611)
Other miscellaneous income 0 59,439
Total other income 96,108 86,182
Loss before provision for income taxes (859,892) (851,764)
Income taxes 0 0
Net loss (859,892) (851,764)
Non-controlling interest 28,665 10,357
Net loss attributable to BioCorRx Inc. $ (831,227) $ (841,407)
Net loss per common share, basic and diluted $ (0.03) $ (0.06)
Weighted average number of common shares outstanding, basic and diluted 25,599,642 15,094,736